Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

Inclusion Criteria: * Diagnosis of solid tumor that overexpresses epidermal growth factor receptor (EGFR) including, but not limited to, the following: * Breast cancer * Lung cancer * Colon cancer * Pancreatic cancer * Head and neck cancer * Kidney cancer * Sarcoma * Advanced disease * Must have failed or become intolerant to prior standard therapy and is no longer likely to respond to such therapy * Measurable or nonmeasurable disease * ECOG performance status 0-1 * ANC ≥ 1,500/mm³ * Platelet count \> 100,000/mm³ * Hemoglobin \> 9 g/dL * Bilirubin \< 1.5 times upper limit of normal (ULN) * Alkaline phosphatase \< 3.0 times ULN (5.0 times ULN if liver has tumor involvement) * Aspartate aminotransferase (AST) and alanine aminotransferase (\*ALT) \< 3.0 times upper limit of normal (ULN) (5.0 times ULN if liver has tumor involvement) * Creatinine clearance \> 30 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study treatment * Recovered from all prior therapy * Prior systemic chemotherapy, immunotherapy, or biological therapy allowed * At least 14 days since prior radiotherapy or systemic therapy * At least 30 days since prior investigational agents * At least 14 days since other prior investigational drugs (for reasons other than the treatment of cancer) Exclusion Criteria: * Untreated or symptomatic central nervous system (CNS) metastases * Concurrent serious systemic disorders (e.g., active infection) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study * Uncontrolled diabetes * Myocardial infarction within the past 6 months * New York Heart Association (NYHA) class III or IV heart failure * Uncontrolled angina * Severe uncontrolled ventricular arrhythmias * Evidence of acute ischemia or active conduction system abnormalities by ECG * Peripheral neuropathy Common Terminology Criteria for Adverse Events (CTCAE) grade \> 2 * Known hypersensitivity to bortezomib, boron, or mannitol * Serious medical or psychiatric illness likely to interfere with study participation * Prior bortezomib and/or cetuximab * Concurrent filgrastim (G-CSF) or other hematologic support during course 1 of study treatment